Literature DB >> 18451155

Pten haploinsufficiency accelerates formation of high-grade astrocytomas.

Chang-Hyuk Kwon1, Dawen Zhao, Jian Chen, Sheila Alcantara, Yanjiao Li, Dennis K Burns, Ralph P Mason, Eva Y-H P Lee, Hong Wu, Luis F Parada.   

Abstract

We previously reported that central nervous system (CNS) inactivation of Nf1 and p53 tumor suppressor genes in mice results in the development of low-grade to high-grade progressive astrocytomas. When the tumors achieve high grade, they are frequently accompanied by Akt activation, reminiscent of the frequent association of PTEN mutations in human high-grade glioma. In the present study, we introduced CNS heterozygosity of Pten into the Nf1/p53 astrocytoma model. Resulting mice had accelerated morbidity, shortened survival, and full penetrance of high-grade astrocytomas. Haploinsufficiency of Pten accelerated formation of grade 3 astrocytomas, whereas loss of Pten heterozygosity and Akt activation coincided with progression into grade 4 tumors. These data suggest that successive loss of each Pten allele may contribute to de novo formation of high-grade astrocytoma and progression into glioblastoma, respectively, thus providing insight into the etiology of primary glioblastoma. The presence of ectopically migrating neural stem/progenitor lineage cells in presymptomatic Pten-deficient mutant brains supports the notion that these tumors may arise from stem/progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451155      PMCID: PMC2760841          DOI: 10.1158/0008-5472.CAN-07-6867

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Subventricular zone astrocytes are neural stem cells in the adult mammalian brain.

Authors:  F Doetsch; I Caillé; D A Lim; J M García-Verdugo; A Alvarez-Buylla
Journal:  Cell       Date:  1999-06-11       Impact factor: 41.582

2.  Differential expression of Rho family GTP-binding proteins and protein kinase C isozymes during C6 glial cell differentiation.

Authors:  S Yoshimura; H Sakai; S Nakashima; Y Nozawa; J Shinoda; N Sakai; H Yamada
Journal:  Brain Res Mol Brain Res       Date:  1997-04

3.  The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.

Authors:  T Maehama; J E Dixon
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

Review 4.  Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas.

Authors:  T C Chen; D R Hinton; R Zidovetzki; F M Hofman
Journal:  Lab Invest       Date:  1998-02       Impact factor: 5.662

Review 5.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

Authors:  L C Cantley; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

6.  The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.

Authors:  H S Huang; M Nagane; C K Klingbeil; H Lin; R Nishikawa; X D Ji; C M Huang; G N Gill; H S Wiley; W K Cavenee
Journal:  J Biol Chem       Date:  1997-01-31       Impact factor: 5.157

7.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

Authors:  K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.

Authors:  A Suzuki; J L de la Pompa; V Stambolic; A J Elia; T Sasaki; I del Barco Barrantes; A Ho; A Wakeham; A Itie; W Khoo; M Fukumoto; T W Mak
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

9.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

10.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

View more
  131 in total

1.  Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.

Authors:  Antoine Italiano; Chun-Liang Chen; Rachael Thomas; Matthew Breen; Françoise Bonnet; Nicolas Sevenet; Michel Longy; Robert G Maki; Jean-Michel Coindre; Cristina R Antonescu
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

Review 2.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

3.  FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Authors:  Bingbing Dai; Russell O Pieper; Dawei Li; Ping Wei; Mingguang Liu; Shiao Y Woo; Kenneth D Aldape; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

4.  Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling.

Authors:  Fuyi Chen; Joel Rosiene; Alicia Che; Albert Becker; Joseph LoTurco
Journal:  Development       Date:  2015-09-23       Impact factor: 6.868

Review 5.  Mouse models of glioblastoma: lessons learned and questions to be answered.

Authors:  Loury Janbazian; Jason Karamchandani; Sunit Das
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

Review 6.  Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity.

Authors:  Evan Noch; Kamel Khalili
Journal:  Cancer Biol Ther       Date:  2009-10       Impact factor: 4.742

Review 7.  Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer.

Authors:  Ralph A Neumüller; Juergen A Knoblich
Journal:  Genes Dev       Date:  2009-12-01       Impact factor: 11.361

8.  What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.

Authors:  Joseph L Kissil; Jaishri O Blakeley; Rosalie E Ferner; Susan M Huson; Michel Kalamarides; Victor-Felix Mautner; Frank McCormick; Helen Morrison; Roger Packer; Vijaya Ramesh; Nancy Ratner; Katherine A Rauen; David A Stevenson; Kim Hunter-Schaedle; Kathryn North
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

Review 9.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

Review 10.  STAT3 regulation of glioblastoma pathogenesis.

Authors:  Núria de la Iglesia; Sidharth V Puram; Azad Bonni
Journal:  Curr Mol Med       Date:  2009-06       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.